Crycision Bio Secures Pre-A Financing to Build Innovative Nanobody Screening Platform

VCBeat (WeChat: vcbeat) has learned that Jingzhun Biotechnology, a startup team focused on the early-stage R&D of novel drugs targeting challenging membrane proteins, recently announced the completion of itsDynamic Balance Capital InvestmentPre-A round of financing will continue to be used for product research and development, including the establishment ofInnovative nanobody screening platform, etc.It was revealed that the company has won favor for three consecutive years since its establishment. Previous investors also included CAS Star andRalph Ventures, with total financing exceeding RMB 10 million.

Nanjing Dynamic Balance Investment & Management Co., Ltd., an investor in this round, stated that, with regard to new drug discovery based on protein structures,Jingzhun Biotechnology has assembled a highly competent team for R&D outsourcing and collaborative development. All founding team members are returnees from overseas. Dr. Tan Jingquan, the founder of Jingzhun Biotechnology, studied under Professor Martin Caffrey, the inventor of membrane protein crystallization technology.After more than a decade of exploration and research, we have accumulated extensive project experience in targeting various drug targets, particularly membrane proteins such as G protein-coupled receptors (GPCRs), which are challenging to characterize but hold significant therapeutic value. Structural elucidation of drug targets serves as the driving force behind new drug development.We have full confidence in the technology platform of Nanjing Jingzhun Biotechnology Co., Ltd. and look forward to its role in accelerating the rapid advancement of innovative drug development in China. As an early-stage healthcare investment institution, Nanjing Dynamic Balance Investment & Management Co., Ltd. will provide comprehensive support for the company’s growth.

As a global leader in the biotechnology industry, Nanjing Jingzhun Biotechnology Co., Ltd. has long been dedicated to the research and development of challenging membrane protein drug targets. JingJingzhun Biotechnology’s technology platform is built upon five core technological pillars: gene editing, membrane protein preparation, structural biology, biomacromolecule screening, and structure-based antibody design.Specializing in the development and engineering of nanobodies targeting membrane proteins (GPCRs). We aim to provide biopharmaceutical companies, biotechnology firms, and research institutes worldwide with high-value, efficient, and highly successful technical services, thereby shortening R&D cycles and reducing costs.

As a CRO company specializing in membrane protein technology,Jingzhun Biotechnology’s technology platform is built upon five core technological pillars: gene editing, membrane protein preparation, structural biology, biomacromolecule screening, and structure-based antibody design.Specializing in the development and engineering of nanobodies targeting membrane proteins (GPCRs).

According to Tan Jingquan, founder of Nanjing Jingzhun Biotechnology Co., Ltd.,Currently, there are relatively few enterprises in China focused on the research and development of nanobodies.Moreover, companies with the capability and focus to conduct R&D on membrane proteins such as GPCRs are exceedingly rare. At this stage, Nanjing Jingzhun Biotechnology Co., Ltd. has secured a significant technological advantage by entering this field. With this round of financing, the company is poised to evolve from having a slight lead to maintaining sustained leadership, ultimately becoming the industry leader in this sector.

In the view of Dr. Tan Jingquan,China’s biopharmaceutical industry is already in a golden period of development and is poised for further explosive growth over the next three to five years.Prior to this, R&D across the entire industry was primarily focused on popular targets, but with the development of the industry, newDrug targets, particularly difficult-to-drug targets, will garner increasing attention, with multi-pass membrane drug targets such as GPCRs gradually becoming mainstream.

Nanjing Jingzhun Biotechnology Co., Ltd. also aims to build an innovative technology platform focused on the early-stage R&D of targeted novel drugs through innovation and collaboration, providing high-quality and reliable services and products to the global biopharmaceutical industry, and striving to fulfill its historical mission of “benefiting humanity through biotechnology.”

Jingzhun Biotechnology was established in March 2018. Its founder, Tan Jingquan, specializes in the structural biology of membrane proteins. During his previous studies and work abroad, he not only engaged in fundamental research on membrane protein drug targets alongside internationally renowned scholars, including his mentor Professor Martin Caffrey and Nobel Laureate Professor Brian Kobilka, but also led drug R&D technical service projects in collaboration with prominent overseas pharmaceutical companies such as Pfizer, Amgen, Novartis, and Agios. Since 2006, he has been dedicated to the structural and functional study of membrane proteins as potential drug targets. Co-founder Dr. Yu Yang has long been engaged in research on nucleic acids and diseases, developing numerous technologies applicable to the early stages of drug development. “Jingzhun Biotechnology combines our respective specialized technologies to create a novel nanobody development platform.”

Ralph Ventures Partner and Founder of the Jiangsu Investors Center, Chen Donghua, stated,Ralph Ventures remains bullish on the future growth potential of the pharmaceutical industry and continues to focus on investment opportunities in high-tech enterprises with core technologies.Nanjing Jingzhun Biotechnology Co., Ltd. boasts a top-tier team of Ph.D. holders from Europe and the United States,Dr. Tan Jingquan, the founder, has also collaborated with top-tier scientists in the field, including Professor Brian Kobilka, a Nobel laureate.Also led drug R&D technical service projects in collaboration with multiple renowned overseas pharmaceutical companies.The team possesses a world-leading, one-stop membrane protein technology development platform, includinga complete technical platform encompassing upstream drug target discovery, structural elucidation of membrane protein drug targets, and structure-based lead compound development.

Yu Xiang of CAS Star stated,The development of innovative drugs targeting G protein-coupled receptors (GPCRs) occupies a significant position in the global pharmaceutical industry,Drugs targeting GPCRs span multiple therapeutic areas, including central nervous system disorders, oncology, and diabetes. Exploring novel targets within the GPCR family and elucidating their relationships with diseases hold substantial commercial value. By leveraging GPCR structure determination, complemented by computer simulation and artificial intelligence technologies, Nanjing Jingzhun Biotechnology Co., Ltd. accelerates the discovery of new targets and lead compounds, thereby playing a significant role in advancing new drug development.